Polygenic risk scores for diverse cohorts
Even though the application of polygenic risk scores (PRSs) in precision medicine has been widely explored, there is limited evidence of its clinical utility across disease areas. To facilitate the development of best practices for PRS calculation, Alicia Martin, and colleagues used data from Global Biobank Meta-analysis Initiative. The researchers explored methods for PRS calculation and prediction accuracy in nine different biobanks for 14 disease endpoints. They outline a framework for PRS analyses of multi-ancestry genome-wide association studies across multiple biobanks and highlight the importance of best practices for PRS in the biobank-scale genomics era.
Read more in Cell Genomics
The Center for Genomic Medicine (CGM) comprises one of the largest and most vibrant hubs of genomic medicine research in the world. The CGM includes 46 faculty collaborating to define the ‘genomic medicine cycle’ – which envisages a genomics community seeking to advance research from basic genomics research to ultimately using genome information for diagnostics and targeted therapeutics. All of our investigators are faculty at Harvard Medical School, and many members of our community are also investigators at the Broad Institute of Harvard and MIT.
